Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder (PTSD). The invention, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes both composition and method claims for Silo’s proprietary approach to preventing or delaying stress-induced behavioral responses. A corresponding patent was issued by the Japan Patent Office earlier this year.
A Notice of Allowance signifies that the USPTO has completed its examination and determined that the application meets the requirements for patentability, meaning the patent will be granted shortly. This development is significant for Silo Pharma as it solidifies its intellectual property position around SPC-15, a key asset in its pipeline for stress-induced psychiatric disorders. The U.S. patent protection is an important component of the company’s strategy as it advances SPC-15 development for PTSD, adding to its growing portfolio of issued and allowed patents in the biopharmaceutical space.
The implications of this patent allowance extend beyond mere legal protection. For Silo Pharma, it provides a competitive edge in the burgeoning field of psychedelic-inspired and stress-related therapeutics, where intellectual property is crucial for attracting investment and partnerships. PTSD is a debilitating condition affecting millions worldwide, and current treatment options are often limited in efficacy and accessibility. SPC-15, if approved, could offer a novel intranasal approach that targets the root of stress-induced fear and anxiety, potentially filling a significant unmet need.
Moreover, the allowance underscores Silo Pharma’s commitment to addressing underserved conditions. The company’s therapeutic focus includes stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio features innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories, enhancing its scientific credibility and potential for breakthrough discoveries.
Investors and industry observers may view this patent milestone as a validation of Silo’s research and development efforts. It could also pave the way for potential licensing opportunities or collaborations with larger pharmaceutical companies seeking to enter the PTSD market. As the company continues to advance SPC-15 through preclinical and clinical stages, the granted patent will provide a foundation for exclusivity, potentially leading to a strong market position upon commercialization.
For more details on this announcement, the full press release is available at https://ibn.fm/Hh4Z6. Additionally, the latest news and updates relating to SILO can be found in the company’s newsroom at https://ibn.fm/SILO.
Silo Pharma’s progress with SPC-15 highlights the growing recognition of mental health disorders as a critical area of biopharmaceutical innovation. With this patent allowance, the company is better positioned to attract the resources needed to bring a potential new therapy to patients suffering from PTSD.
